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A Highly Heterogeneous HIV-1 Epidemic
in the Central African Republic
The Central African Republic has been strongly
affected by the human immunodeficiency virus
(HIV) epidemic. Although itself sparsely populated,
the republic borders five other African countries and
is crossed by the trans-African highway, which con-
nects West and Central Africa with East Africa
(Figure 1).  Wide genetic variation reported among
HIV-1 subtypes (on the basis of small numbers of
samples) suggests multiple introductions of HIV into
the republic (1). However, except in small studies
and unpublished reports (2), the distribution and
serologic reactivities of HIV within the Central Af-
rican Republic have not been characterized.
The need to conduct HIV surveillance has also
been highlighted by reports of highly divergent
strains of HIV-1 group O from neighboring
Cameroon (3,4) and by recent findings that some of
these strains were not reliably detected by current
antibody screening tests (5-7). To assess the preva-
lence and distribution of HIV in the Central African
Republic, the local Ministry of Health AIDS Pro-
gram, assisted by the Centers for Disease Control
and Prevention (CDC), initiated a nationwide sen-
tinel surveillance survey in late 1994. Sentinel
surveillance has been useful for obtaining informa-
tion on HIV infection (8). In particular, serial
sentinel studies have permitted the spread of HIV
to be monitored and trends to be followed over time.
In this report, we present findings on the distribu-
tion of HIV-1 infections and serologic reactivities of
HIV in the Central African Republic.
From October through December 1994, a nation-
wide sentinel surveillance survey was conducted in
10 cities and towns: Bambari, Bangassou, Bangui,
Berberati, Bossangoa, Bozoum, Bria, Gamboula,
M’Baiki, and Mobaye (Figure 1). The two primary
population groups included were women attending
prenatal clinics and male and female attendees at
sexually transmitted disease (STD) clinics. Two ad-
ditional sites in the capital city, Bangui, were
included to perform testing for laborers and univer-
sity students.
Serum samples, anonymous and without any
personal identifiers, were collected and transported
to the National Public Health Laboratory in Bangui.
Testing for this study was supported by CDC, which
used U.S. Public Health Service guidelines for con-
firmation (9). All sera were tested with the Genetic
Systems HIV-1/2-enzyme immunoassay (EIA) kit
and all repeat positive sera were confirmed by HIV-
1 Western blot (Cambridge Biotech). Specimens
positive by initial EIA but negative for HIV-1 by
Western blot or indeterminate were further tested
for HIV-2 antibodies by an HIV-2 Western blot (Cam-
bridge Biotech). In addition, samples from 11 sites
(with sufficient quantity) that were positive by ini-
tial EIA were serotyped by using peptides
representing the known HIV-1 subtypes A-F and the
divergent HIV-1 group O (10,11).
A total of 2,259 persons were tested from 17 sites
from 10 cities and towns. Between 2.7% and 30.7%,
by site, were positive for HIV-1 by repeat EIA and
Western blot confirmation (Table). A higher HIV-1
prevalence (25.3% to 30.7%) was observed among
STD clinic attendees, whereas the prevalence among
women at prenatal care clinics was generally >5%
and as high as 16.7% (the exception was the lower
rate in women from the prenatal care clinic in
Gamboula. No HIV-2 infection was detected among
the 175 persons whose serum was initially positive
by EIA but negative for HIV-1 by Western blot or
indeterminate by Western blot for HIV-2.
Among 247 samples serotyped by peptide EIA,
173 were HIV-1 positive by Western blot, 60 were
indeterminate, and 14 were HIV-1 negative (Figure
2). No divergent HIV-1 group O infection was found
among these persons. Serotype C (24%) was most
prevalent among the monoreactive specimens. Many
of the specimens were reactive to multiple peptides;
16 (9%) did not recognize any of the peptides and
may represent more divergent HIV-1 strains.
The high seroprevalences (Table) indicate that
HIV-1 infection is a serious public health problem
in a number of groups in the Central African Re-
public. The wide variation of HIV-1 prevalence even
Figure 1.  Map of the Central African Republic with
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within similar groups in a region illustrates the het-
erogeneous nature of this epidemic. The HIV-1
prevalence was especially high among STD clinic
attendees. Although the number of specimens from
STD clinic attendess was relatively small, the high
proportion of HIV-infected persons at all four STD
clinics is a cause for concern. Because Bangui and
Bambari are major crossroads for transport in the
Central African Republic as well as on the east-west
highway to other countries, the potential for further
HIV spread is great.
Since STDs are associated with (and may facili-
tate) HIV transmission (12), STD diagnosis and
control are integral components of HIV prevention.
CDC, with financial support from the U.S. Agency
for International Development, recently helped es-
tablish two pilot STD treatment sites in Bambari
and Bria.
Although HIV-2, which is endemic to West Af-
rica, has not been reported from the Central African
Republic, reports of HIV-1 Group O from neighbor-
ing Cameroon highlighted the importance of
monitoring these strains. Although no HIV-2 or di-
vergent HIV-1 group O infections were found in this
study, the extremely wide pattern of serologic reac-
Table. Prevalence of HIV-1 by sentinel site/population
Positive by
Sentinel site/Population Western blot (%) Total
Bambari
Prenatal clinic women 20 (13.3) 150
STD clinic attendees 23 (26.7) 86
Bangassou
Prenatal clinic women 16 (10.0) 160
Bangui
Prenatal clinic women A 20 (13.3) 150
Prenatal clinic women B 8 ( 5.3) 150
STD clinic attendees 20  (25.3) 79
University students 14  ( 9.3) 150
Workers 23 (15.4) 149
Berberati
Prenatal clinic women 16  (10.7) 150
Bossangoa
Prenatal clinic women 9 ( 6.0) 148
Bozoum
Prenatal clinic women 20  (13.2) 151
STD attendees 23 (30.7) 75
Bria
Prenatal clinic women 22 (16.7) 132
STD attendees 24 (30.4) 79
Gamboula
Prenatal clinic women 4 ( 2.7) 150
M’Baiki
Prenatal clinic women 8 ( 5.3) 150
Mobaye
Prenatal clinic women 9 ( 6.0) 150
Total number tested 2,259
Figure 2. Serotype distribution among 173 HIV-1-in-
fected persons. Letters indicate serologic reactivities
to peptides to the given HIV-1 subtypes A-F. Sera re-
active to two different subtype peptides are given as a
combination of two letters. Multiple refers to sera that
reacted to more than 2 different subtype peptides.
Nonreactive refers to sera that did not react to any of
the peptides used.
tivity among HIV-1-infected persons suggests a very
heterogenous distribution of HIV-1 strains in the
republic. This is confirmed by the wide variety of
genotypes (subtypes) found in the republic in the
past (1), and suggests that in certain populations,
at least, multiple subtypes of HIV-1 have been in-
troduced over time (7). This finding may be
important to the development of effective future HIV
vaccines for use in this region.
Since the quantity of specimens collected in this
large-scale survey was not sufficient for genetic
analysis, further studies are needed to characterize
the genetic diversity of HIV in the Central African
Republic. Given the limited search for HIV variants
and the diversity of HIV subtypes recognized thus
far, both a wider distribution of the HIV strains and
the existence of yet more divergent variants seem
likely (7).  For these reasons, CDC plans to assist
the Republic’s National AIDS Control Program with
further characterization of virus for divergent sub-
types; these findings indicate the need for more
resources to help the program maintain and expand
HIV and STD prevention.
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